CDMO business GenScript ProBio and Eutilex Co. Ltd. committed to developing anti-cancer immunotherapy technology jointly announced that the parties entered into strategic collaboration on plasmid and virus process development and manufacturing for multiple CAR-T programs in order to achieve win-win cooperation and accelerate the development of global immunotherapy. According to the collaboration agreement, by means of complementary advantages and strong alliances, Eutilex will use GenScript's high-quality one-stop plasmid and virus platform for plasmid and virus process development and manufacturing in its CAR-T programs. Supported by Eutilex's unique immunotherapy technology and GenScript ProBio's experience in plasmid and virus manufacturing, this collaboration will expedite the launch of cell therapy products.